FindTrial
Sign In

Circulating tumor cell changes and efficacy of neoadjuvant chemotherapy for triple-negative breast cancer

Circulating tumor cell changes and efficacy of neoadjuvant chemotherapy for triple-negative breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025207
Enrollment
Unknown
Registered
2019-08-16
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple-negative breast cancer

Interventions

Sensitivity group:Neoadjuvant chemotherapy based on taxanes or/and anthracyclines
Drug resistance group :Neoadjuvant chemotherapy based on taxanes or/and anthracyclines

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. triple-negative breast cancer confirmed by breast biopsy; 2. stage III breast cancer (IIIA-C) assessed by CT or MRI; 3. neoadjuvant chemotherapy; 4. informed consent of patients and their family members.

Exclusion criteria

Exclusion criteria: 1. use of second-line chemotherapy regimen; 2. bilateral breast cancer; 3. inflammatory breast cancer; 4. pregnant or breast-feeding; 5. distant metastasis; 6. a history of other cancers or chest radiotherapy; 7. abnormal blood test or other infectious symptoms.

Design outcomes

Primary

MeasureTime frame
Efficacy of neoadjuvant chemotherapy at 18 weeks.;—

Secondary

MeasureTime frame
Efficacy of neoadjuvant chemotherapy at 6 and 12 weeks.;Detection of circulating tumor cells;Miller-Payne grading score;—

Countries

China

Contacts

Public ContactJianyi Li

Shengjing Hospital of China Medical University

sjbreast@yeah.net+86 18940257177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026